AR020054A1 - COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS - Google Patents
COMPOSICIoN QUE COMPRENDE UN ADENOVIRUSInfo
- Publication number
- AR020054A1 AR020054A1 ARP990100656A ARP990100656A AR020054A1 AR 020054 A1 AR020054 A1 AR 020054A1 AR P990100656 A ARP990100656 A AR P990100656A AR P990100656 A ARP990100656 A AR P990100656A AR 020054 A1 AR020054 A1 AR 020054A1
- Authority
- AR
- Argentina
- Prior art keywords
- adenovirus
- composition understanding
- virus
- virus preparations
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Abstract
Composicion que contiene virus en una formulacion que contiene un polihidroxi hidrocarburo regulada para mantener un ph en el intervalo de aproximadamente7 a aproximadamente 8,5 a una temperatura en el orden de aproximadamente 2sC a 27sC; preparadosde virus concentrado y purificado y métodos para concentrar ypurificar dichos preparados de virus. Estos virus se utilizan para terapia génica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2446298A | 1998-02-17 | 1998-02-17 | |
US7964398A | 1998-05-15 | 1998-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR020054A1 true AR020054A1 (es) | 2002-04-10 |
Family
ID=26698472
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990100656A AR020054A1 (es) | 1998-02-17 | 1999-02-23 | COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS |
ARP070104577A AR063315A2 (es) | 1998-02-17 | 2007-10-16 | Composicion que comprende un virus, y metodos para concentrar y purificar preparados de virus |
ARP070104576A AR063314A2 (es) | 1998-02-17 | 2007-10-16 | Metodos para purificar preparados de virus |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104577A AR063315A2 (es) | 1998-02-17 | 2007-10-16 | Composicion que comprende un virus, y metodos para concentrar y purificar preparados de virus |
ARP070104576A AR063314A2 (es) | 1998-02-17 | 2007-10-16 | Metodos para purificar preparados de virus |
Country Status (25)
Country | Link |
---|---|
EP (4) | EP1526173B1 (es) |
JP (3) | JP4358434B2 (es) |
KR (5) | KR100918187B1 (es) |
CN (2) | CN101164623B (es) |
AR (3) | AR020054A1 (es) |
AT (3) | ATE341614T1 (es) |
AU (1) | AU757976B2 (es) |
BR (1) | BR9908015A (es) |
CA (2) | CA2320419C (es) |
CO (1) | CO4820440A1 (es) |
DE (3) | DE69933433T2 (es) |
DK (1) | DK1054955T3 (es) |
ES (2) | ES2290613T3 (es) |
HK (3) | HK1073481A1 (es) |
HU (1) | HU226015B1 (es) |
ID (1) | ID28298A (es) |
IL (2) | IL137510A0 (es) |
MY (1) | MY141641A (es) |
NO (1) | NO20004104L (es) |
PE (1) | PE20000265A1 (es) |
PL (1) | PL197747B1 (es) |
PT (1) | PT1054955E (es) |
SK (1) | SK11842000A3 (es) |
TW (1) | TWI232107B (es) |
WO (1) | WO1999041416A2 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
JP4492826B2 (ja) | 1996-11-20 | 2010-06-30 | イントロジェン セラピューティクス,インコーポレイテッド | アデノウイルスベクターの産生および精製のための改良された方法 |
EP1133316B1 (en) * | 1998-11-16 | 2009-01-21 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
EP1263461A4 (en) * | 2000-03-07 | 2009-08-12 | Merck & Co Inc | ADENOVIRUS FORMULATIONS |
US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
US20020064860A1 (en) | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
AU2002218535A1 (en) * | 2000-12-12 | 2002-06-24 | Japan Tobacco Inc. | Pharmaceutical composition containing an active with a hemolytic action and a surfactant |
CA2469491A1 (en) | 2001-12-12 | 2003-06-19 | Kerrie Setiawan | Composition for viral preservation |
US20030153065A1 (en) * | 2002-01-14 | 2003-08-14 | Genvec, Inc. | Composition and method for maintaining non-enveloped viral vectors |
MXPA04006995A (es) * | 2002-01-18 | 2005-07-13 | Schering Ag | Formulaciones estabilizadas de adenovirus. |
ATE435906T1 (de) | 2004-02-23 | 2009-07-15 | Crucell Holland Bv | Verfahren zur reinigung von viren |
CA2586107A1 (en) | 2004-11-03 | 2006-05-18 | Introgen Therapeutics Inc. | A novel method for the production and purification of adenoviral vectors |
EP1831352B1 (en) | 2004-12-13 | 2011-07-13 | CANJI, Inc. | Cell lines for production of replication-defective adenovirus |
DK1869171T4 (en) | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
CN1961961B (zh) * | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
WO2007070392A2 (en) | 2005-12-12 | 2007-06-21 | Canji, Inc. | Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase |
WO2007123961A2 (en) * | 2006-04-20 | 2007-11-01 | Wyeth | Purification processes for isolating purified vesicular stomatitis virus from cell culture |
US10041049B2 (en) | 2008-11-03 | 2018-08-07 | Janssen Vaccines & Prevention B.V. | Method for the production of adenoviral vectors |
MX356669B (es) | 2009-05-02 | 2018-06-08 | Genzyme Corp | Terapia genica para trastornos neurodegenerativos. |
CA2786835C (en) | 2010-02-15 | 2021-08-31 | Crucell Holland B.V. | Method for the production of ad26 adenoviral vectors |
WO2012038367A1 (en) | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
WO2012041669A1 (en) | 2010-09-27 | 2012-04-05 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
US9045728B2 (en) * | 2010-12-02 | 2015-06-02 | Oncolytics Biotech Inc. | Liquid viral formulations |
TW201233803A (en) | 2010-12-02 | 2012-08-16 | Oncolytics Biotech Inc | Lyophilized viral formulations |
SG194449A1 (en) * | 2011-04-29 | 2013-12-30 | Oncolytics Biotech Inc | Methods of purifying viruses using gel permeation chromatography |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
KR102044051B1 (ko) | 2012-03-12 | 2019-11-12 | 얀센 백신스 앤드 프리벤션 비.브이. | 터미널 말단이 변경된 재조합 아데노바이러스의 배치 |
US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
WO2013139916A1 (en) | 2012-03-22 | 2013-09-26 | Crucell Holland B.V. | Vaccine against rsv |
DK2988780T3 (en) | 2013-04-25 | 2019-04-08 | Janssen Vaccines & Prevention Bv | STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES |
US10294279B2 (en) | 2013-06-17 | 2019-05-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
KR20170004966A (ko) * | 2014-05-28 | 2017-01-11 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 바이러스 감소 방법 |
PL3283634T3 (pl) | 2015-04-14 | 2019-10-31 | Janssen Vaccines & Prevention Bv | Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem |
BR112017027448A2 (pt) | 2015-07-07 | 2018-09-04 | Janssen Vaccines & Prevention Bv | vacina contra rsv |
BR112017028449A2 (pt) | 2015-07-07 | 2018-09-04 | Janssen Vaccines & Prevention Bv | polipeptídeos rsv f pré-fusão solúveis estabilizados |
CA3018139A1 (en) | 2016-04-05 | 2017-10-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
SG11201807913XA (en) | 2016-04-05 | 2018-10-30 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f proteins |
SG11201810078PA (en) | 2016-05-30 | 2018-12-28 | Janssen Vaccines & Prevention Bv | Stabilized pre-fusion rsv f proteins |
EP3472327B1 (en) | 2016-06-20 | 2020-08-19 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
US10744196B2 (en) | 2016-07-14 | 2020-08-18 | Janssen Vaccines & Prevention B.V. | HPV vaccines |
WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
WO2019021305A1 (en) * | 2017-07-24 | 2019-01-31 | Ella Foundation | VACCINE AGAINST FOOT AND MOUTH DISEASE |
EP3681533A1 (en) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against rsv |
EP3990031A4 (en) * | 2019-06-28 | 2023-08-09 | Takeda Pharmaceutical Company Limited | METHODS FOR PURIFYING ADENO-ASSOCIATED VIRUS |
JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法-sars-cov-2ワクチン |
JP2024509756A (ja) | 2021-02-19 | 2024-03-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化された融合前rsv fb抗原 |
WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
CN115989321A (zh) * | 2021-08-17 | 2023-04-18 | 上海行深生物科技有限公司 | 病毒制剂、用于配制病毒制剂的溶液及其用途 |
WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE299213C (es) * | ||||
US4147772A (en) * | 1976-02-03 | 1979-04-03 | Merck & Co., Inc. | Vaccine stabilizer |
GB1575155A (en) * | 1978-04-11 | 1980-09-17 | Merck & Co Inc | Vaccine stabilizer |
BE866330A (fr) * | 1978-04-25 | 1978-10-25 | Merck & Co Inc | Procede de fabrication d'un agent de stabilisation de vaccin |
US5532220A (en) | 1987-08-31 | 1996-07-02 | The Regents Of The University Of California | Genetic mechanisms of tumor suppression |
DD299213A7 (de) * | 1988-05-04 | 1992-04-09 | Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De | Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung |
DD295927A5 (de) * | 1988-05-06 | 1991-11-14 | Saechsisches Serumwerk Gmbh Dresden, | Immobilisiertes immunologisch aktives reagens |
EP2113569A1 (en) | 1993-10-25 | 2009-11-04 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
KR100368686B1 (ko) * | 1994-12-29 | 2003-12-01 | 주식회사 엘지생명과학 | 수크로즈를이용한세포와바이러스의분리방법 |
FR2742756B1 (fr) * | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
-
1999
- 1999-02-12 ES ES04030395T patent/ES2290613T3/es not_active Expired - Lifetime
- 1999-02-12 DE DE69933433T patent/DE69933433T2/de not_active Expired - Lifetime
- 1999-02-12 KR KR1020087008929A patent/KR100918187B1/ko not_active IP Right Cessation
- 1999-02-12 DK DK99906690T patent/DK1054955T3/da active
- 1999-02-12 WO PCT/US1999/001873 patent/WO1999041416A2/en active IP Right Grant
- 1999-02-12 CN CN2007101670867A patent/CN101164623B/zh not_active Expired - Fee Related
- 1999-02-12 EP EP04030394A patent/EP1526173B1/en not_active Expired - Lifetime
- 1999-02-12 EP EP04030395A patent/EP1526174B1/en not_active Expired - Lifetime
- 1999-02-12 KR KR1020007008878A patent/KR100862169B1/ko not_active IP Right Cessation
- 1999-02-12 DE DE69936948T patent/DE69936948T2/de not_active Expired - Lifetime
- 1999-02-12 HU HU0100670A patent/HU226015B1/hu not_active IP Right Cessation
- 1999-02-12 KR KR1020097022935A patent/KR101018992B1/ko not_active IP Right Cessation
- 1999-02-12 DE DE69942708T patent/DE69942708D1/de not_active Expired - Lifetime
- 1999-02-12 PL PL342847A patent/PL197747B1/pl not_active IP Right Cessation
- 1999-02-12 CA CA2320419A patent/CA2320419C/en not_active Expired - Fee Related
- 1999-02-12 EP EP99906690A patent/EP1054955B1/en not_active Expired - Lifetime
- 1999-02-12 BR BR9908015-0A patent/BR9908015A/pt not_active Application Discontinuation
- 1999-02-12 AU AU26538/99A patent/AU757976B2/en not_active Ceased
- 1999-02-12 CN CNB998050989A patent/CN100374551C/zh not_active Expired - Fee Related
- 1999-02-12 AT AT99906690T patent/ATE341614T1/de not_active IP Right Cessation
- 1999-02-12 CA CA2723040A patent/CA2723040A1/en not_active Abandoned
- 1999-02-12 SK SK1184-2000A patent/SK11842000A3/sk unknown
- 1999-02-12 ID IDW20001574A patent/ID28298A/id unknown
- 1999-02-12 PT PT99906690T patent/PT1054955E/pt unknown
- 1999-02-12 AT AT04030395T patent/ATE371020T1/de not_active IP Right Cessation
- 1999-02-12 JP JP2000531596A patent/JP4358434B2/ja not_active Expired - Fee Related
- 1999-02-12 IL IL13751099A patent/IL137510A0/xx unknown
- 1999-02-12 AT AT06019642T patent/ATE478945T1/de not_active IP Right Cessation
- 1999-02-12 EP EP06019642A patent/EP1741777B1/en not_active Expired - Lifetime
- 1999-02-12 TW TW088102219A patent/TWI232107B/zh not_active IP Right Cessation
- 1999-02-12 KR KR1020097004676A patent/KR100991683B1/ko not_active IP Right Cessation
- 1999-02-12 KR KR1020087008928A patent/KR100912362B1/ko not_active IP Right Cessation
- 1999-02-12 ES ES99906690T patent/ES2272053T3/es not_active Expired - Lifetime
- 1999-02-15 MY MYPI99000542A patent/MY141641A/en unknown
- 1999-02-16 PE PE1999000137A patent/PE20000265A1/es not_active Application Discontinuation
- 1999-02-16 CO CO99009282A patent/CO4820440A1/es unknown
- 1999-02-23 AR ARP990100656A patent/AR020054A1/es active IP Right Grant
-
2000
- 2000-07-25 IL IL137510A patent/IL137510A/en not_active IP Right Cessation
- 2000-08-16 NO NO20004104A patent/NO20004104L/no not_active Application Discontinuation
- 2000-12-01 HK HK05106734A patent/HK1073481A1/xx not_active IP Right Cessation
- 2000-12-01 HK HK00107727A patent/HK1028416A1/xx not_active IP Right Cessation
-
2006
- 2006-02-07 JP JP2006030336A patent/JP2006166925A/ja not_active Withdrawn
-
2007
- 2007-05-10 HK HK07104995.0A patent/HK1097413A1/xx not_active IP Right Cessation
- 2007-10-16 AR ARP070104577A patent/AR063315A2/es unknown
- 2007-10-16 AR ARP070104576A patent/AR063314A2/es unknown
-
2010
- 2010-07-08 JP JP2010156257A patent/JP2010213727A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR020054A1 (es) | COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS | |
DE3750422D1 (de) | Translation von mrna. | |
ATE429210T1 (de) | Orale flüssige zusammensetzungen | |
ATE236886T1 (de) | 2,4-dioxo-imidazolidin-derivate | |
DE69938255D1 (de) | Verfahren und zusammensetzung zur konservierung von adenoviren | |
ES552627A0 (es) | Procedimiento para la preparacion de carbamatos de fenilo | |
BR9814340A (pt) | Derivados de indol como inibidores de fator xa | |
TR199902626T2 (xx) | Enflamasyon tedavisi i�in ikameli benzopiran t�revleri. | |
BR0010220A (pt) | Compostos de pirimidinona | |
CO5050303A1 (es) | Composicion farmaceutica para tratar infecciones virales y metodos para su preparacion su aplicacion | |
EA200100298A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5 | |
ES2181234T3 (es) | Producto de combinacion que asocia un acido nucleico a una sustancia que desorganiza la matriz extracelular para la terapia genica. | |
ATE298741T1 (de) | Polyaromatische verbindungen zur behandlung von herpes-infektionen | |
PT1016711E (pt) | Processo de inactivacao de virus de envelope numa preparacao viral de adenovirus | |
DK1123414T3 (da) | Antisense-modulering af integrin alpha 4.ekspression | |
DE69518840D1 (en) | N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren | |
ES2104133T3 (es) | Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico. | |
HUP0004780A2 (hu) | Prosztaglandin agonisták felhasználása merevedési rendellenességek vagy impotencia kezelésében | |
DK0634396T3 (da) | Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer | |
ATE179164T1 (de) | Hiv-proteaseinhibitoren | |
BR9801085A (pt) | Processo para a preparação de moenomicina a. | |
ES2196783T3 (es) | Nuevo procedimiento de preparacion de la fexofenadina. | |
DE69739167D1 (de) | Zusammensetzungen zur modulierung der länge von telomeren | |
CR6302A (es) | Nuevos usos farmaceuticos par inhibidores nos | |
ECSP992859A (es) | Composiciones que contienen virus y metodos para concentrar preparados de virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |